Intervacc AB

Research Intervacc AB (IVACC) on Bullrun: market cap SEK 370.12M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is SEK 370.12M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025SEK 20.09M-SEK 80.82M-SEK 66.92M-57.2%-0.27SEK 160.89MSEK 108.00KSEK 274.91M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-24SEK 370.12Mn/an/an/a

About Intervacc AB

Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. The company's product pipeline includes Strangvac, a vaccine against equine strangles for horses; INV274, antigens for a vaccine against streptococcus suis for the treatment of weaned piglets; and INV412, a multi-component vaccine to protect against several bacteria which cause mastitis for treating cows.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Intervacc AB's market cap?

Intervacc AB's market capitalization is SEK 370.12M.

What does Intervacc AB do?

Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. The company's product pipeline includes Strangvac, a vaccine against equine strangles for horses; INV274, antigens for a vaccine against streptococcus suis for the treatment of weaned piglets; and INV412, a multi-component vaccine to protect against several bacteria which cause mastitis for treating cows. It also engages in marketing and distribution of veterinary products in the Nordic markets, which includes vaccines and pharmaceuticals for swine, horses, cattle, and sheep.